Taken together, the combination of pazopanib and PD-L1 blockade may be a promising future therapeutic option for STS, and the final results of an ongoing trial (A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma; ClinicalTrials.gov Identifier: NCT03798106) may help to confirm this premise. The gene discussed is CD274; the disease is telomere syndrome.